메뉴 건너뛰기




Volumn 35, Issue SUPPL. 1, 2012, Pages 28-33

Personalized therapy in breast cancer

Author keywords

Beast cancer; Cancer genome projects; HER2; Intrinsic molecular subtypes; Multigene signatures; Personalized therapy; Predictive factors; Prognostic factors

Indexed keywords

CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE; KI 67 ANTIGEN;

EID: 84856491137     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/0003349736     Document Type: Article
Times cited : (10)

References (32)
  • 1
    • 67650674658 scopus 로고    scopus 로고
    • The worldwide overview: New results for systemic adjuvant therapies
    • San Antonio, TX, USA, Dec 13-16
    • Peto R for the Early Breast Cancer Trialists' Collaborative Group The worldwide overview: new results for systemic adjuvant therapies. Presentation at the 30th Annual SABCS, San Antonio, TX, USA, Dec 13-16, 2007.
    • (2007) Presentation at the 30th Annual SABCS
    • Peto, R.1
  • 2
    • 80054100462 scopus 로고    scopus 로고
    • Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) ASCO Ann Meet Proc 2011
    • abstr 507
    • Guarneri V, Frassoldati A, Bottini A, Generali DG, Cagossi K, et al.: Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). ASCO Ann Meet Proc 2011. J Clin Oncol 2011;29(suppl):abstr 507.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Guarneri, V.1    Frassoldati, A.2    Bottini, A.3    Generali, D.G.4    Cagossi, K.5
  • 4
    • 82355192663 scopus 로고    scopus 로고
    • TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer ASCO Ann Meet Proc 2011
    • abstr 505
    • Chang JCN, Mayer IA, Forero-Torres A, Nanda R, Goetz MP, et al.: TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. ASCO Ann Meet Proc 2011. J Clin Oncol 2011;29(suppl):abstr 505.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Jcn, C.1    Mayer, I.A.2    Forero-Torres, A.3    Nanda, R.4    Goetz, M.P.5
  • 6
    • 79952258750 scopus 로고    scopus 로고
    • First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer
    • San Antonio, TX, USA, Dec 8-12, Cancer Research 2010; 70 abstr S3
    • Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M; on Behalf of the NeoALTTO Study Team: First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd Annual CTRC-AACR SABCS, San Antonio, TX, USA, Dec 8-12, 2010; Cancer Research 2010; 70:abstr S3.
    • (2010) 33rd Annual CTRC-AACR SABCS
    • Baselga, J.B.1
  • 7
    • 83255175479 scopus 로고    scopus 로고
    • Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM 4450g/BO21976)
    • Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Song C, Tong B, Chu YW, Perez EA: Trastuzumab emtansine (T-DM1) vs. trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Eur J Cancer 2011;47:S330.
    • (2011) Eur J Cancer , vol.47
    • Hurvitz, S.1    Dirix, L.2    Kocsis, J.3    Gianni, L.4    Lu, J.5    Vinholes, J.6    Song, C.7    Tong, B.8    Chu, Y.W.9    Perez, E.A.10
  • 9
    • 78951482208 scopus 로고    scopus 로고
    • Deconstructing the molecular portraits of breast cancer
    • Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
    • (2011) Mol Oncol , vol.5 , pp. 5-23
    • Prat, A.1    Perou, C.M.2
  • 11
    • 79960980007 scopus 로고    scopus 로고
    • Strategies for subtypes -Dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    • Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes -dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
    • (2011) Ann Oncol , vol.22 , pp. 1736-1747
    • Goldhirsch, A.1    Wood, W.C.2    Coates, A.S.3    Gelber, R.D.4    Thurlimann, B.5    Senn, H.J.6
  • 13
    • 79959288369 scopus 로고    scopus 로고
    • A supervised risk predictor of breast cancer based on biological subtypes
    • abstr 11008
    • Parker J: A supervised risk predictor of breast cancer based on biological subtypes. ASCO Ann Meet Proc 2008. J Clin Oncol 2008;26(suppl):abstr 11008.
    • (2008) ASCO Ann Meet Proc 2008. J Clin Oncol , vol.26 , Issue.SUPPL.
    • Parker, J.1
  • 14
    • 80052877920 scopus 로고    scopus 로고
    • Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis ASCO Ann Meet Proc 2011
    • abstr 1028
    • Von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, et al.: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. ASCO Ann Meet Proc 2011. J Clin Oncol 2011; 29(suppl):abstr 1028.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Von Minckwitz, G.1    Kaufmann, M.2    Kuemmel, S.3    Fasching, P.A.4    Eiermann, W.5
  • 15
    • 33745603978 scopus 로고    scopus 로고
    • An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
    • DOI 10.1038/sj.onc.1209415, PII 1209415
    • Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008. (Pubitemid 43990755)
    • (2006) Oncogene , vol.25 , Issue.28 , pp. 3994-4008
    • Doane, A.S.1    Danso, M.2    Lal, P.3    Donaton, M.4    Zhang, L.5    Hudis, C.6    Gerald, W.L.7
  • 17
    • 71749091235 scopus 로고    scopus 로고
    • Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays
    • Albain KS, Paik S, van't Veer L: Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009;18(suppl 3):S141-5.
    • (2009) Breast , vol.18 , Issue.SUPPL. 3
    • Albain, K.S.1    Paik, S.2    Van'T Veer, L.3
  • 19
    • 77951637777 scopus 로고    scopus 로고
    • Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study
    • Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, et al.: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
    • (2010) J Clin Oncol , vol.28 , pp. 1829-1834
    • Dowsett, M.1    Cuzick, J.2    Wale, C.3    Forbes, J.4    Mallon, E.A.5    Salter, J.6    Quinn, E.7    Dunbier, A.8    Baum, M.9    Buzdar, A.10    Howell, A.11    Bugarini, R.12
  • 20
    • 81155133281 scopus 로고    scopus 로고
    • Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer
    • Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, et al.: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-8.
    • (2011) J Clin Oncol , vol.29 , pp. 4273-8
    • Cuzick, J.1    Dowsett, M.2    Pineda, S.3    Wale, C.4    Salter, J.5    Quinn, E.6    Zabaglo, L.7    Mallon, E.8    Green, A.R.9    Ellis, I.O.10    Howell, A.11    Buzdar, A.U.12
  • 21
    • 79954827812 scopus 로고    scopus 로고
    • Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20
    • Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL, Wolmark N: Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast cancer Res Treat 2011;127:133-42.
    • (2011) Breast Cancer Res Treat , vol.127 , pp. 133-142
    • Tang, G.1    Shak, S.2    Paik, S.3    Anderson, S.J.4    Costantino, J.P.5    Geyer Jr., C.E.6    Mamounas, E.P.7    Wickerham, D.L.8    Wolmark, N.9
  • 22
    • 80052418906 scopus 로고    scopus 로고
    • Additional value and potential use of the 70-gene prognosis signature in nodenegative breast cancer in daily clinical practice
    • Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC: Additional value and potential use of the 70-gene prognosis signature in nodenegative breast cancer in daily clinical practice. Ann Oncol 2009;22:2021-30.
    • (2009) Ann Oncol , vol.22 , pp. 2021-2030
    • Bueno-De-Mesquita, J.M.1    Sonke, G.S.2    Van De Vijver, M.J.3    Linn, S.C.4
  • 32
    • 79959838081 scopus 로고    scopus 로고
    • Integrated genomic analyses of ovarian carcinoma
    • Network TCGA: Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
    • (2011) Nature , vol.474 , pp. 609-615
    • Tcga, N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.